Profile: Quest Diagnostics Inc (DGX.N)
13 Sep 2019
Quest Diagnostics Incorporated, incorporated on September 20, 1996, is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers.
Diagnostic Information Services
The Company provides information and insights based on routine, non-routine and advanced clinical testing and anatomic pathology testing, and related services, offering customers the test menu. The Company offers testing solutions, including services for the predisposition, diagnosis, treatment and monitoring of cancers and other diseases, and offer tests in various fields, including endocrinology, immunology, neurology and oncology. It is focused on providing solutions and insights to its customers, based on the testing that it performs and its medical, information and connectivity assets. It provides integrated, diagnostic information services that include both anatomic pathology and clinical laboratory testing, enabling it to offer patients and clinicians a complete analysis. The Company offers access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers, and phlebotomists in physician offices. It provides interpretive consultation through medical and scientific staffs in the industry.
The Company is a provider of infectious disease diagnostic information services. It also provides diagnostic solutions for infectious diseases, including its Focus Diagnostics offerings for Zika, West Nile Virus, Severe acute respiratory syndrome (SARS) and Influenza A H1N1. It is engaged in the neurology diagnostics market, in cardiovascular diagnostic information services, including its CardioIQ offering, and in cancer diagnostics, including its QuestVantage offerings. It is engaged in providing testing for the detection of employee use of drugs of abuse, offering a range of solutions, including urine, hair, blood and oral fluid tests. The Company is a provider of biometric wellness screenings, flu shots and related preventative services. It offers biometric wellness screenings to employer populations through its patient service centers and on-site through its network of mobile examiners and nurses. In addition to a range of screening options, it also offers Blueprint for Wellness and private label reporting, analytics and incentive management services. These services are sold directly to employers and through reseller partnerships with various health plans.
The Company's Quanum health information technology solutions help healthcare organizations and clinicians empower health through diagnostic insights by taking advantage of its information assets, including various years of test result data, and its technology prowess, including its history of providing information technology for diagnostic information services. It provides diagnostic information services in various markets outside the United States. It has laboratory facilities in Gurgaon, India; Mexico City, Mexico, and San Juan, Puerto Rico. It also provides testing services, and inpatient anatomic pathology and medical director services, at hospital laboratories. Its services primarily are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.
The Company is a provider of risk assessment services for the life insurance industry. In addition, it offers healthcare organizations and clinicians health information technology solutions. ExamOne is a provider of risk assessment services to the life insurance industry in North America. It also provides risk assessment services for insurance companies operating outside North America. Its risk assessment services comprise underwriting support services, including data gathering, paramedical examinations and clinical laboratory testing and analytics, designed to assist life insurance companies objectively to evaluate the mortality risks of applicants. As of December 31, 2016, specimen collections and paramedical examinations were performed by its network of paramedical examiners at the applicant's home or workplace, but they also were offered at approximately 600 company patient service centers in the United States and approximately 120 additional locations in North America.
The Company's healthcare information technology offerings include its Quanum EHR product and its ChartMaxx enterprise content management system for hospitals. Its Quanum EHR offering enables clinicians to generate a complete record of a clinical patient encounter, automates and streamlines the clinician's workflow, provides clinical decision support tools, captures patient encounter notes and lab and radiology results and enables communication with patients and other clinicians. Its MyQuest patient healthcare portal enables patients to manage their healthcare and medical information and, among other things, use their smartphone or computer to receive and archive their Quest Diagnostics test results, find a Quest Diagnostics location and schedule appointments.
The Company competes with Laboratory Corporation of America Holdings, Inc.
Quest Diagnostics Inc
500 Plaza Dr
SECAUCUS NJ 07094-3619
Company Web Links
- RPT-EXCLUSIVE-Philips, under investigation in U.S. and Brazil, fired whistleblower who warned of graft
- UPDATE 1-Opko Health says over 400,000 customers likely affected by data breach
- Opko Health says over 400,000 customers likely affected by data breach
- PRESS DIGEST - Wall Street Journal - June 5
- Quest Diagnostics says data breach could have hit 11.9 million patients